Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting
NCT00095316Phase 3Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2004
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in candidiasis comparing Placebo with Caspofungin (2 arms). Primary endpoint: Incidence of Invasive Candidiasis up to 35 days. Started Oct 2004; status: terminated.
02
Drugs
caspofungin
03
Conditions
candidiasis
Beyond the preview
Go deeper on NCT00095316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095316.